-
Sector Analysis
NewPetrochemicals Capacity and Capital Expenditure Outlook by Region, Countries, Companies, Commodity, Projects and Forecast to 2030
Petrochemicals Capacity & Capital Expenditure (Capex) Overview The petrochemicals capacity was 2600.06 million tonnes per annum (mtpa) in 2023. Asia, the Middle East, and the Former Soviet Union are the top regions contributing to capacity additions in the upcoming years. In the Middle East, most capacity additions are in Iran while in FSU, the majority of capacity additions are in Russia. Petrochemicals Capacity and Capex Outlook, 2023-2030 (mtpa) Buy the Full Report for More Insights on Petrochemicals Capacity and Capex...
-
Product Insights
ESNE NHSFT – Colchester Orthopedic Surgery Center – Essex
Equip yourself with the essential tools needed to make informed and profitable decisions with our ESNE NHSFT - Colchester Orthopedic Surgery Center - Essex report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Net Present Value Model: Fezolinetant
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fezolinetant Drug Details Fezolinetant (ESN-364) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – fezolinetant
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fezolinetant Drug Details Fezolinetant (ESN-364) is under development for the treatment of menopause-related vasomotor...
-
Sector Analysis
Australia In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.
GlobalData’s “Australia In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Australia In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The Australia In Vitro Diagnostics Market report provides key information and data on: • Annualized market revenues (USD), volume...
-
Sector Analysis
Australia In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.
GlobalData’s “Australia In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Australia In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The Australia In Vitro Diagnostics Market report provides key information and data on: • Annualized market revenues (USD), volume...